SEC Form DEF 14A filed by Ionis Pharmaceuticals Inc.
$IONS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/16/2026 | Outperform → Peer Perform | Wolfe Research | |
| 5/19/2026 | $115.00 | Buy | Citigroup |
| 4/21/2026 | $110.00 | Buy | Canaccord Genuity |
| 4/10/2026 | $104.00 | Outperform | Raymond James |
| 1/28/2026 | $95.00 | Overweight | Barclays |
| 10/8/2025 | $80.00 | Neutral → Overweight | Analyst |
| 9/26/2025 | $65.00 | Sell → Neutral | Goldman |
| 9/3/2025 | $70.00 | Market Perform → Outperform | BMO Capital Markets |
8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern TimeIonis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ionis Pharmaceuticals, Inc.For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and
- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing on CDR-SB - - Biomarker response: Diranersen is the first tau-directed therapy to demonstrate robust reductions in both CSF total tau, with mean reductions of 50–65%, and brain tau pathology, as measured by PET, across all studied doses in a Phase 2 study - - Dose response: CDR-SB results favored diranersen versus placebo across all studied doses; higher doses wer
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrome, a rare, severe and lifelong neurological disorder. Dravet syndrome typically begins in infancy and is associated with prolonged seizures, developmental delays, cognitive impairments and an increased risk of sudden death. "The first participant to receive ION337 in the ASCEND study marks an important step toward advancing a potential disease modifying therapy for people living with Dravet syndrome," said Holly Kordasiewicz, Ph.D., executive vice president, chief developme
Submission status for IONIS PHARMS INC's drug TRYNGOLZA (AUTOINJECTOR) (SUPPL-4) with active ingredient OLEZARSEN SODIUM has changed to 'Approval' on 06/24/2026. Application Category: NDA, Application Number: 218614, Application Classification: Efficacy
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
Wolfe Research downgraded Ionis Pharma from Outperform to Peer Perform
Citigroup initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $115.00
Canaccord Genuity initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $110.00
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately."We are pleased to welcome Dr. Hantson to the board," said Joseph Loscalzo, M.D., Ph.D., chairman of the Ionis Board of Directors. "Ludwig's biopharma executive leadership experience will be especially meaningful as Ionis prepares for a steady cadence of new commercial launches, including two additional independent launches this year, while continuing to scale its operations as a fully integrated biotechnology company."Dr. Hantson has more than 30 years of leadership experience at biopharmac
– Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will be retiring at the end of their term and Peter N. Reikes will be rejoining as a director. The changes will be effective June 4, 2026. Ms. Parshall has served as a director since September 2000. Previously, she served as Ionis' chief operating officer from December 2007 through December 2017 and as chief financial officer from June 1994 through December 2012. Ms. Parshall joined Ionis in 1991 and served in various executive ro
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
- TRYNGOLZA® (olezarsen) showed increasing demand in FCS driven by strong launch execution – - Olezarsen sNDA accepted by the FDA for Priority Review; sHTG launch preparations on track – – Increasing annual TRYNGOLZA peak net sales guidance to >$3B for sHTG – - Zilganersen NDA for Alexander disease accepted for Priority Review, paving way for Ionis' first independent launch from leading neurology pipeline – - Strong first-quarter performance and outlook for the year supports improved 2026 financial guidance - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the first quarter ended March 31, 2026. "Ionis' stro
- TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch – - Olezarsen sHTG launch preparations on track, sNDA submitted - - Exceeded 2025 financial guidance, 2026 guidance reflects commitment to independently deliver a steady cadence of innovative medicines to patients - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025. "2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system. ThecaFlex DRx™ is an investigational implantable device designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and accessibility for a broader population of people living with neurologic disorders. ThecaFlex DRx™ has been in development since 2019, with the PIERRE and PIERRE-PK clinical studies for nusinersen curren